3种保肝用药方案治疗乙型肝炎肝硬化的最小成本分析

Cost-minimization Analysis of 3 Kinds of Therapeutic Regimens for Hepatic Cirrhosis Caused by Hepatitis B

目的:评价3种保肝用药方案治疗乙型肝炎肝硬化的经济学效果。方法:将遴选出的95例乙型肝炎肝硬化患者随机分为A、B、C组,在应用注射用门冬氨酸鸟氨酸的基础上,分别联合应用注射用肝水解肽、注射用还原型谷胱甘肽钠、复方二氯醋酸二异丙胺注射液进行保肝治疗,疗程均为7～21d,观察疗效,并进行最小成本分析。结果:A、B、C组的治疗时间分别为(14.42±6.44)、(12.40±5.89)、(15.79±6.19)d;总有效率分别为67.7%、80.0%、76.5%,差异无统计学意义(P>0.05);总成本分别为(4853.58±2128.43)、(3425.37±1585.51)、(4959.67±1909.49)元。结论:B组方案最佳。

OBJECTIVE：To evaluate the economic efficacy of 3 kinds of therapeutic regimens in the treatment of hepatic cirrhosis caused by hepatitis B.METHODS：A total of 95 patients with hepatic cirrhosis caused by hepatitis B were randomized into 3 groups.3 groups received L-ornithine L-aspartate for injection.3 groups were additionally given Heparolysate for injection,Re-duced glutathione sodium for injection or Compound diisopropylamine dichloroacetate injection for 7 to 21 days,respectively.The curative effects were recorded and the cost-minimization analysis was conducted.RESULTS：In group A,group B and group C,the course of treatments were（14.42±6.44）days,（12.40±5.89）days and（15.79±6.19）days,respectively;the total effective rates of group A,group B and group C were 67.7%,80.0% and 76.5%,respectively,showing no statistical significance among 3 groups（P0.05）;the total costs were（4 853.58±2 128.43）yuan,（3 425.37±1 585.51）yuan and（4 959.67±1 909.49）yuan,respectively.CONCLUSION：The therapeutic regimen for group B is the best one among 3 kinds of therapeutic regimens in terms of cost-minimization.